Our data suggest that CVID and sIgAD patients show a humoral and cellular immune response to the SARS-CoV-2 vaccine that is present several months after vaccination, but the detectable anti-spike IgG antibody levels in CVID patients are lower than in healthy controls, and selective IgA patients. The gene discussed is CD79A; the disease is selective IgA deficiency disease.